Sentences with phrase «pancreatic neuroendocrine tumors»

For the first time, researchers have shown that a certain protein becomes overabundant in pancreatic neuroendocrine tumors, allowing them to thrive.

Finding new treatments is critical because less than 5 percent of patients with pancreatic neuroendocrine tumors respond to everolimus, the most commonly used pharmaceutical, François said.

In the first set of experiments, the Johns Hopkins scientists sequenced nearly all protein - encoding genes in 10 of the 68 samples of pancreatic neuroendocrine tumors and compared these sequences with normal DNA from each patient to identify tumor - specific changes or mutations.

Zajac - Kaye's group discovered that a single protein is behind the process that allows pancreatic neuroendocrine tumors to thrive.

Jobs had a rare form of pancreatic cancer known as pancreatic neuroendocrine tumor (pNET).

Over the last few years a number of cancer types have been found to harbor frequent and recurrent mutations in the histone variant H3.3 and two other associated genes, DAXX and ATRX, notably pancreatic neuroendocrine tumors and childhood gliomas.

Concurrent Presentation of High - Grade Lymphoma and Metastatic Pancreatic Neuroendocrine Tumor 14 Years After Renal Transplant

Some types of malignant pancreatic neuroendocrine tumors, such as islet cell tumors, have a better prognosis than pancreatic exocrine cancers.

For information on endocrine pancreatic cancer, see the PDQ summary on Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment.

These growths, including pancreatic neuroendocrine tumors and carcinoid tumors, form from hormone - releasing cells, and the tumors can lead to higher levels of hormones than normal.

Researchers investigated non-hormonal pancreatic neuroendocrine tumors in 68 men and women.

To do this, they used genetically engineered mice with pancreatic neuroendocrine tumors.

Researchers from the «Angiogenesis signaling pathways» research group of the Institute of Biomedical Investigation of Bellvitge (IDIBELL), led by Dr. Mariona Graupera, have unveiled the potential therapeutic benefit of a selective inhibitior of the PI3 - kinase (PI3K) protein in pancreatic neuroendocrine tumors (PanNETs).

Pancreatic neuroendocrine tumors are increasingly common, which medical experts and researches have attributed to better diagnostic imaging, an aging population and heightened awareness of the disease stemming from the 2011 death of Apple Inc. co-founder Steve Jobs.

Pancreatic neuroendocrine tumors, often referred to as «islet cell tumors» are a type of cancer that arises from hormone - releasing cells in the pancreas.

«Pancreatic neuroendocrine tumors — pancreatic NETs, pNETs or islet cell tumors — are tumors that form from the abnormal growth of neuroendocrine cells in the pancreas,» says lead author Hala Elnakat Thomas, PhD, research assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, and member of the Cincinnati Cancer Consortium and UC Cancer Institute's Pancreatic Cancer Center.

«PI3K protein: Potential new therapeutic target in pancreatic neuroendocrine tumors.»

My particular areas of interest are GI and pancreatic neuroendocrine tumors and pancreatic pathology.

My research mainly focuses on pathobiology of GI and pancreatic neuroendocrine tumors and identification of diagnostic, prognostic and therapeutic biomarkers for colorectal and pancreatic cancer.

In 2011, based on initial findings from two clinical trials, the Food and Drug Administration approved sunitinib and everolimus for patients with pancreatic neuroendocrine tumors.